Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a progressive condition that eventually leads to end-stage renal disease. A phase 3 trial of tolvaptan (TEMPO 3:4; NCT00428948) and its open-label extension (TEMPO Extension Japan: TEMPO-EXTJ; NCT01280721) were conducted in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Muto, Satoru, Okada, Tadashi, Shibasaki, Yoshiyuki, Ibuki, Tatsuki, Horie, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357671/
https://www.ncbi.nlm.nih.gov/pubmed/34089122
http://dx.doi.org/10.1007/s10157-021-02083-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357671/
https://www.ncbi.nlm.nih.gov/pubmed/34089122
http://dx.doi.org/10.1007/s10157-021-02083-y

Ejemplares similares